Moderna Announces Pricing of Initial Public Offering
December 06 2018 - 8:40PM
Business Wire
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced the pricing of its initial public
offering of 26,275,993 shares of common stock at a public offering
price of $23.00 per share, before underwriting discounts and
commissions. Moderna’s common stock is expected to begin trading on
The Nasdaq Global Select Market on December 7, 2018 under the
ticker symbol “MRNA.” All of the common stock is being offered by
Moderna. The gross proceeds of the offering, before deducting
underwriting discounts and commissions and other offering expenses
payable by Moderna, are expected to be $604.3 million, excluding
any exercise of the underwriters’ option to purchase additional
shares. The offering is expected to close on December 11, 2018,
subject to satisfaction of customary closing conditions. Moderna
has granted the underwriters a 30-day option to purchase up to an
additional 3,941,398 shares of Moderna’s common stock at the
initial public offering price, less underwriting discounts and
commissions.
Morgan Stanley, Goldman Sachs & Co. LLC and J.P. Morgan are
acting as joint lead book-running managers for the offering. BofA
Merrill Lynch, Barclays Capital Inc. and Piper Jaffray & Co.
are acting as book-running managers for the offering. Oddo BHF SCA,
Oppenheimer & Co. Inc., Needham & Company, LLC and Chardan
are acting as co-managers for the offering.
Registration statements relating to the shares being sold in
this offering have been filed with the Securities and Exchange
Commission and were declared effective on December 6, 2018. The
offering is being made only by means of a prospectus. Copies of the
final prospectus may be obtained, when available, from Morgan
Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick
Street, 2nd Floor, New York, New York 10014; from Goldman Sachs
& Co. LLC, Attention: Prospectus Department, 200 West Street,
New York, New York 10282, telephone: 1-866-471-2526, facsimile:
212-902-9316, or email: prospectus-ny@ny.email.gs.com; or from J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, telephone:
1-866- 803-9204, or email: prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities law of any
such state or jurisdiction.
About Moderna
Moderna pioneers the discovery and development of messenger RNA
(mRNA) therapeutics and vaccines to direct the body’s cells to
produce intracellular or secreted proteins that can have a
therapeutic or preventive benefit for both patients and healthy
individuals.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181206006060/en/
Media:Jason GlashowHead of Corporate
Communications617-674-5648jason.glashow@modernatx.comInvestors:Lorence
KimChief Financial Officer617-209-5849lorence.kim@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024